Conducting countless custom analytics projects to answer business questions for pharmaceutical companies worldwide reveals a universal truth: Every research method has limitations, and only when used in combination can pharma teams get a holistic picture of their market. Additionally, what happens in a clinical trial may not follow the same patterns in a real-world setting.
While epidemiology is the gold standard for sizing patient populations, shifts and trends are likely happening right now that impact market sizing data and epidemiology studies.
By combining real-world evidence with epidemiology studies for market sizing in pharma, research teams can increase the speed and timeliness of their insights, understand the broader disease population, and generate more current and balanced trending and forecasting.
Director, Data & Analytics, DRG